Skip to content
Staging environment — review version. Do not share.

VNS and DBSResearch Radar

Long-term benefit in the most difficult cases of depression: new evidence supporting vagus nerve stimulation

Achieving improvement in treatment-resistant depression (TRD) is difficult — but maintaining that improvement over time is often even more challenging. Patients with marked levels of resistance…

By João L. de Quevedo, MD, PhD

Published on · Last reviewed on · 4 min read

In this article
  1. Why durability matters in TRD
  2. The RECOVER trial: a long-term perspective
  3. Key findings: sustained and emerging benefit
  4. A unique feature of VNS: slow onset, strong durability
  5. What this means for patients and clinicians
  6. Future perspectives

Achieving improvement in treatment-resistant depression (TRD) is difficult — but maintaining that improvement over time is often even more challenging. Patients with marked levels of treatment resistance not only respond less frequently to antidepressant interventions but, when they do respond, have high relapse rates. This challenge has long limited the real-world impact of many available treatments.

A recently published report from the RECOVER trial, entitled “Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression,” presents some of the strongest evidence to date that vagus nerve stimulation (VNS), as an adjunctive therapy, offers not only clinical benefit — but exceptional durability of benefit over two years, even in patients with profound chronicity and resistance to multiple previous treatments.

Why durability matters in TRD

In highly treatment-resistant major depression, relapse is the rule rather than the exception. Data from large studies, such as STAR*D, show that, after multiple treatment failures, the probability of maintaining remission for one year with additional medications is well below 5%. Even with effective acute treatments, such as electroconvulsive therapy (ECT), approximately half of patients relapse within a few months.

For this reason, durability of benefit — not just the initial response — is a critical outcome in evaluating interventions for markedly resistant TRD.

The RECOVER trial: a long-term perspective

The RECOVER trial followed 214 adults with markedly treatment-resistant major depression, each with at least four failed antidepressant trials in the current episode, many of whom had also failed to respond to ECT and transcranial magnetic stimulation (TMS). After completing one year of blinded adjunctive VNS, participants continued with open-label active VNS for another year and were assessed for outcomes at 18 and 24 months.

Importantly, outcomes were assessed across multiple clinically relevant domains, including:

  • Depressive symptoms
  • Daily functioning
  • Quality of life
  • A “tripartite” composite measure integrating all three

This multidimensional approach reflects what truly matters to patients — how they feel, how they function, and how they live.

Key findings: sustained and emerging benefit

The results are striking:

  • Approximately 80% of participants who achieved meaningful clinical benefit at 12 months maintained that benefit at 18 and 24 months, across measures of symptoms, functioning, and quality of life.
  • Among those with substantial benefit or remission at 12 months, durability rates were even higher, with more than 90% maintaining meaningful benefit at two years.
  • Relapse rates were consistently low, especially among those who achieved more robust responses.
  • Notably, benefit continued to emerge over time: among participants without meaningful benefit at 12 months, approximately 30–40% went on to show clinically relevant improvement at 24 months.

These improvements were not explained by changes in medications, ECT, TMS, or ketamine/esketamine use, reinforcing that the sustained benefit was attributable to continued VNS therapy rather than intensification of other treatments.

A unique feature of VNS: slow onset, strong durability

Unlike many antidepressant treatments that act rapidly but are associated with early relapses, VNS follows a different therapeutic trajectory. Clinical benefit generally builds gradually over months, with maximal effects sometimes emerging after a year or more. The RECOVER data confirm that this slow onset is accompanied by remarkable long-term stability, making VNS particularly well suited to patients with chronic, highly resistant depression.

What this means for patients and clinicians

For individuals who have exhausted standard pharmacological and neuromodulation options, these findings are highly relevant. They suggest that VNS is not merely another acute intervention but a long-term, potentially disease-modifying strategy capable of producing sustained improvement in symptoms, functioning, and quality of life.

From a clinical perspective, the study reinforces the importance of aligning expectations with patients: VNS is not a quick fix, but, for the right patient, it offers a realistic chance of durable recovery where other treatments have failed.

Future perspectives

The RECOVER trial represents one of the most comprehensive assessments of long-term outcomes in markedly treatment-resistant depression. Its findings support a broader role for VNS in advanced TRD programs and highlight the need to prioritize durability — not just short-term response — in defining treatment success.

At the UTHealth Houston Center for Interventional Psychiatry, these results align closely with our mission: to offer evidence-based, innovative, and sustainable treatments for patients facing the most severe and refractory forms of depression.

References

  1. Conway CR, Rush AJ, Aaronson ST, et al. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report. International Journal of Neuropsychopharmacology. 2026;29(1):pyaf080. doi:10.1093/ijnp/pyaf080 · doi:10.1093/ijnp/pyaf080

Related content